Cardinal Health (CAH)
(Delayed Data from NYSE)
$110.76 USD
-0.65 (-0.58%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $110.74 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
CAH 110.76 -0.65(-0.58%)
Will CAH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CAH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CAH
Cardinal Health (CAH) Stock Falls Amid Market Uptick: What Investors Need to Know
CAH Stock May Gain Following the Distribution Agreement With Telix
CAH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
Here's Why Cardinal Health (CAH) Gained But Lagged the Market Today
Other News for CAH
Interesting CAH Put And Call Options For November 15th
These stocks are expected to benefit from the reshoring trend currently happening
BlackRock Basic Value VI Fund Q2 2024 Commentary
BlackRock Mid-Cap Value Fund Q2 2024 Commentary
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix?